Morgan Stanley GHC Event
I listened yesterday. Was nice to see TW do the presentation himself. While not a lot new to us who follow the company closely, it was evident that the moderator was surprised by the potential of both K and T. There is obviously doubt about HZNP's peak sales projections, but in our experience they are likely low balled rather than exaggerated (underpromise - overdeliver). Execution will drive this stock (IMHO) as asset values continue to increase. Nice explanation of the J-code and how it affects a company's ability to reach patients. In essence, a temporary J-code means each patient has to be individually approved, but a permanent one allows blanket approval (good to know).